Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 443Thoracic 190CNS 141Gynecologic 139Breast 136Genitourinary 57Sarcoma 55Dermatologic 30Head & Neck 24Tumor-Agnostic 18Lymphoid 15Endocrine 14Other solid neoplasm 10Other hematologic neoplasm 9Plasma cell 5NET 3Myeloid 3Other neoplasm 1Classical hematology 1

Conditions

Neuroendocrine Tumors 3Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 18Everolimus 13Temozolomide 12Nivolumab 10pembrolizumab 9cabozantinib 8Capecitabine 8Sunitinib 7lenvatinib 5Magnetic Resonance Spectroscopy 5Etoposide 5lanreotide 4gallium Ga 68 dotatate 4Specimen Handling 4Ipilimumab 4Cisplatin 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3surufatinib 3pazopanib 3avelumab 3Octreotide 3Injections 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Bevacizumab 3sintilimab 2fosbretabulin 2fludarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Bevacizumab × NET × Clear all
NCT00398320 2017-03-01

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors

Stanford University

Phase 2 Completed
40 enrolled 9 charts
EndocrineNET

Neuroendocrine Tumors

NCT00137774 2013-04-09

Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors

Dana-Farber Cancer Institute

Phase 2 Completed
34 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01203306 2010-09-16

XELBEVOCT

University of Turin, Italy

Phase 2 Unknown
42 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡